Halofenate

This classification denotes a uricosuric agent and anti-lipidemic agent with the molecular formula C19H17ClF3NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K9TZK4MNO6, chemically known as (p-chlorophenyl)((alpha,alpha,alpha-trifluoro-m-tolyl)oxy)acetic acid ester with n-(2-hydroxyethyl)acetamide but generally known as halofenate, which bears US NIH Compound Identifier 33584. European Medicines Agency schedules Halofenate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07999MIG. The term HALOFENATE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 23, No. 10 1969, List 9). HALOFENATE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule halofenate under HS 29242995 and SITC 51479. As of Q4 2014, HALOFENATE remains the US FDA Preferred Term for this commodity. Halofenate bears US NLM identifiers UMLS ID C0018541 and NCI Concept Code C83805. SMILES: CLC1CCC(C(OC2CC(CCC2)C(F)(F)F)C(=O)OCCNC(=O)C)CC1.